Clinical Trials
11 trialsNCT01844986 2025-12-10
SOLO-1
AstraZeneca
Phase 3 Active not recruiting
NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT03522246 2025-06-24
ATHENA
pharmaand GmbH
Phase 3 Active not recruiting
NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
NCT04934670 2024-08-27
2002
Xenikos
Phase 3 Terminated
NCT02789254 2023-12-28
FLYSYN-101
Synimmune GmbH
Phase 1/2 Completed
NCT04126590 2023-09-01
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
Changchun Intellicrown Pharmaceutical Co. LTD
Phase 1 Unknown
NCT00725283 2018-08-07
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
GlaxoSmithKline
Phase 1 Completed
NCT01520558 2017-06-29
CNDO-109-AANK for AML in First Complete Remission (CR1)
Coronado Biosciences, Inc.
Phase 1/2 Unknown
NCT00343720 2008-03-13
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
Millennium Pharmaceuticals, Inc.
Phase 2 Completed